Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 854070, 10 pages
http://dx.doi.org/10.1155/2015/854070
Review Article

Kidney Injury Molecule-1 and Cardiovascular Diseases: From Basic Science to Clinical Practice

1Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 1, 11129 Belgrade, Serbia
2Center for Endocrine Surgery, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Koste Todorovica 8, 11000 Belgrade, Serbia
3Department of Pathology, Faculty of Medicine, University of Belgrade, Dr Subotica Starijeg 1, 11129 Belgrade, Serbia

Received 24 July 2015; Revised 27 October 2015; Accepted 4 November 2015

Academic Editor: Hua Zhue

Copyright © 2015 Branislava Medić et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Despite the recent findings concerning pathogenesis and novel therapeutic strategies, cardiovascular disease (CVD) still stays the leading cause of morbidity and mortality in patients with renal dysfunction, especially acute kidney injury (AKI). Early detection of patients with impaired renal function with cardiovascular risk may help ensure more aggressive treatment and improve clinical outcome. Kidney injury molecule-1 (KIM-1) is a new, promising marker of kidney damage which is currently the focus of countless studies worldwide. Some recent animal and human studies established KIM-1 as an important marker of acute tubular necrosis (ATN) and reliable predictor of development and prognosis of AKI. Food and Drug Administration (FDA) in USA acclaimed KIM-1 as an AKI biomarker for preclinical drug development. Recent data suggest the importance of monitoring of KIM-1 for early diagnosis and clinical course not only in patients with various forms of AKI and other renal diseases but also in patients with cardiorenal syndrome, heart failure, cardiopulmonary bypass, cardiothoracic surgical interventions in the pediatric emergency setting, and so forth. The aim of this review article is to summarize the literature data concerning KIM-1 as a potential novel marker in the early diagnosis and prediction of clinical outcome of certain cardiovascular diseases.